© 2024 Alpha Spread Limited. All Rights Reserved.
www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.
You don't have any saved screeners yet
Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.
Good morning, ladies and gentlemen, and welcome to the ATS Automation First Quarter Conference Call and Webcast. This call is being recorded on August 11th, 2021, at 8:30 a.m. Eastern Time. Following the presentation, we'll conduct a question-and-answer session, instructions will be provided at that time for you to queue up for questions. [Operator Instructions].I'll now turn the conference over to Shereen Zahawi, Director of Investor Relations at ATS. Please go ahead.
Thank you, operator, and good morning, everyone. Your main hosts today are Andrew Hider, Chief Executive Officer of ATS; and Ryan McLeod, Chief Financial Officer. For those who joined us by phone, our remarks are accompanied by a slide deck, which is available at atsautomation.com.Before we begin, I am required to provide the following statement respecting forward-looking information, which is made on behalf of ATS and all its representatives on this call. You are cautioned that the oral statements made on this call will contain forward-looking information that involves risks and uncertainties, including those introduced by the COVID-19 pandemic. The actual results could differ materially from a conclusion, forecast or projection in the forward-looking information. Certain material factors or assumptions were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information. Additional information about the material factors that could cause actual results to differ materially from the conclusion, forecast or projection in the forward-looking information and the material factors or assumptions that were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information are contained in ATS' filings with the Canadian provincial securities regulators.Now, it's my pleasure to turn the call over to Andrew.
Thank you, Shereen. Good morning, ladies and gentlemen, and thank you for joining us. We're pleased to report a strong quarter for ATS, including record order bookings and backlog with robust organic revenue and good progress on margin expansion, we're building on recent momentum. We continue to execute our M&A agenda and closed 2 acquisitions in the quarter, BioDot and CIM. BioDot is now part of our Life Sciences group, which expands our capabilities and offerings for this important end market. CIM joins our Process Automation Solutions business and helps expand our customer and geographical reach. We're excited to welcome both businesses to the ATS family. Additionally, CFT, which we acquired late in the fourth quarter, is performing in line with our expectations, and the integration is progressing well.Today, I will update you on business conditions, and then Ryan will provide his report. Starting with our financial value drivers. Q1 revenues were $510 million, up 57% from Q1 last year and up 28% sequentially, driven by the addition of CFT, which closed in late March 2021 as well as broad-based business strength. Organically, revenues grew 28% year-over-year, an improvement that was augmented by the impact COVID-19 had on Q1 revenues last year. Q1 order bookings were $637 million, almost double last year's level and up 38% sequentially. CFT and BioDot contributed approximately 1/3 of order bookings growth versus Q1 last year, and we saw strong bookings across most markets with large customer awards in Life Sciences and Transportation. Our adjusted EBIT margin for the quarter was 12.8%, representing over 360 basis points of margin expansion versus Q1 of last year and over 40 basis points of expansion sequentially.Moving to our outlook. Our backlog grew to $1.2 billion at the end of Q1, providing us with good revenue visibility and a solid business foundation for fiscal 2022. As vaccine rollouts picked up pace in a number of our global markets, we're seeing an improvement in customer site access and reduced travel restrictions compared to the same period last year. While the situation remains fluid, I'm proud of how our people adapted and our ability to find creative ways to serve our customers.By market, we saw positive conditions in Life Sciences with strength in key sectors of medical devices, pharma and radiopharma. We continue to win mandates related to COVID-19 as we help our customers in the fight against the pandemic. This work represented around 10% of our Life Sciences bookings and 6% of our total bookings in Q1. We are also seeing more traditional non-COVID related opportunities in the funnel as customers revive pre-pandemic investment priorities. Life Sciences represented 64% of our bookings this quarter, and we expect it to remain a key market for APS.In EV, we're seeing robust activity levels from both traditional OEMs and newcomers, looking to expand their electrical offering. We continue to be selective in the opportunities we pursue and won a number of mandates, including a large award in the quarter. Our long track record and proven expertise in battery assembly and test, make us a trusted partner as our customers navigate the complexities of evolving battery technologies.We saw strength in food and beverage, and with the addition of CFT, we're now separately reporting activity in this market. In other areas of consumer, we saw good activity in warehouse automation, while cosmetics still hasn't recovered yet to pre-pendent levels. In energy, we continue to execute and see opportunities in nuclear for both refurbishment and decommissioning in Canada and globally. On after sales services, order bookings remained healthy and revenues were up double digits versus Q1 last year and in line with our expectations. We continue to utilize our regional service networks and digital tools to facilitate access to customer sites as we navigate pandemic travel restrictions in some geographies. We see opportunities to expand the aftermarket services footprint to support additional areas of our business and create a better customer experience.To summarize our outlook, this was another quarter of strong order bookings that has led to record order backlog. Our funnel remains healthy, and we're seeing a pickup in customer activity. The pandemic environment continues to introduce some timing and approval uncertainty when it comes to our customers' buying decisions. However, we're encouraged by recent customer demand signals.Moving to the ABM, our continuous improvement playbook. This was another busy quarter for our teams with multiple virtual Kaizens and problem-solving workshops held across the Company with a focus on both operational and commercial improvement. A few ABM highlights, we held 15 Kaizens and problem-solving workshops across various ATS divisions. These events drove improvements in multiple areas, including bookings, sales and operations. One division in our Life Sciences group used a kaizen to eliminate approximately 600 hours it spend annually on non-value-added time by improving workflow and shop floor layouts. At CFT, we hold the workshop aimed at improving the on-time delivery of spare parts. By implementing the daily visual management system, we expect on-time delivery to improve to 90% or better in the next 3 months from approximately 80% today.Our industrial automation team hosted another joint customer event in Q1, focused on simplifying the process for handling change orders and significantly shortening the length of the process. This is the second collaboration with customers and another positive outcome. We also launched our second global virtual ABM boot camp on the back of a similar event in Q1 -- in Q4 that received positive company-wide feedback. The Tamp runs over a 6-week period and provides self-paced learning and real-time discussions with ABM leaders. This modified virtual format enables us to continue scaling our training and demonstrates our businesses across ATS by using ABM to deliver tangible results.On M&A, acquisitions continue to be an important complement to ATS' organic growth. The integration of the CFT acquisition, which closed late in the fourth quarter, is progressing well with performance tracking to plan. As you know, CFT scaled up our food and beverage exposure and complement their other food business, MARCO. During the quarter and during this first quarter, we acquired 2 businesses, BioDoT and CIM. BioDot expands our Life Sciences capabilities in low volume dispensing and enhances our position in the point-of-care and lab automation end markets. CIM, a system integrator with a focus on industrial automation, adds to our capabilities and expands our customer base and reach in the Pharma market. CIM now operates as part of our Process Automation Solutions business.We will continue to cultivate and evaluate acquisition opportunities, consistent with our proven strategy. Of course, timing of acquisitions will be variable, and our approach to deploying our balance sheet will be disciplined and strategic.In summary, first quarter results present another proof point of the strength and resiliency of our business. Going forward, our priorities remain unchanged, ensuring the health and safety of our employees, serving our customers well and creating value for our shareholders. Our strong backlog provides good revenue visibility, while our healthy balance sheet enables us to pursue our M&A playbook when strategic targets arise.Now, I will turn the call over to Ryan. Ryan, over to you.
Thank you, Andrew, and good morning, ladies and gentlemen. This morning, I'll provide an overview of our Q1 operating results that featured growth in revenues and operating margins and record order bookings and backlog. I will then provide color on our balance sheet.I'll start with the operating results. And as an opening comment, we are pleased with the pace of year-over-year growth. In part, this reflected both the impact of the pandemic on results in Q1 last year and the contribution of acquisitions. That said, our global operations have continued to [indiscernible] using our ABM playbook with strong performance delivered as a result of our ongoing focus on growth and margin improvement.Bookings were $637 million, up 96% over Q1 last year when activity levels were depressed by the onset of the pandemic. Organic growth in bookings was 74%, partially offset by an 8% headwind from foreign exchange translation. Organic growth primarily reflected new orders in Life Sciences, headlined by a $120 million order bookings from a global medical device company for a fully automated manufacturing solution that we announced in early June. Acquisitions contributed 30% with the majority of incremental order bookings coming in food and beverage due to the addition of CFT. Compared to Q4, order bookings were up 38% sequentially, reflecting increased orders in food and beverage due to CFT and continued strength in Life Sciences. On a trailing 12-month basis, our book-to-bill ratio was 1.2:1, positioning us well for this fiscal year.Moving to revenues. Q1 revenue grew 57% compared to the prior year. Organic revenue growth was 28% due to higher order backlog entering the year as well as year-over-year growth in services and after sales parts revenues, while foreign exchange was a 6% headwind compared to Q1 last year. Acquired companies added 35% to our growth. Revenues from acquired companies, primarily CFT and BioDot, were ahead of plan due to the timing of project activities. CFT typically experiences some seasonality in its business, with higher revenues in Q1 and Q2 of ATS' fiscal year due to targeted equipment deliveries ahead of the harvest seasons of some of its key end markets. BioDot continued to experience favorable tailwinds due to COVID-related activity. Sequentially, our revenues increased 28% from Q4, primarily reflecting CFT and BioDot.Our record Q1 ending backlog of $1.25 billion was 37% higher than last year's $909 million. Organic growth in backlog was 24% due to higher order bookings through the year, partially offset by foreign exchange translation, with the balance of the increase related to backlog acquired with CFT and BioDot. Life Sciences represented 59% of our period end order backlog, with food and leverage representing 11%, up from 1% a year ago. Looking forward, our revenue conversion for Q2 is estimated to be in the higher end of the 35% to 40% range of backlog. While we are pleased with the strength and resiliency of our business, COVID will continue to influence the timing of customer orders and service revenues in the near term.Moving to margins. Q1 gross margin was 28.2%, up over 380 basis points from last year. Higher gross margin reflected improvements made in the cost structure of our core business through our reorganization, improved program execution, increased service revenues and other continuous improvement efforts. As expected, these improvements were partially offset by acquired businesses, which operated with lower gross margin. We also had lower recoveries under the Canadian Emergency Wage Subsidy program compared to the prior year.Our teams have done an excellent job adapting to the current environment. Globally, ATS operations continue to effectively address the challenges of operating with a significant portion of our workforce at home, the presence of extra health and safety measures in our facilities, similar protocols at customer locations and travel restrictions.Moving to SG&A. Expenses were $26.7 million higher than Q1 last year. This year's costs included $11.3 million of acquisition-related amortization and $2.1 million of M&A transaction costs. Excluding comparable items in both periods, Q1's SG&A was $69.8 million, $21.9 million higher than last year, reflecting incremental SG&A costs from acquired companies, primarily CFT for the full quarter and BioDot for one month. First quarter stock compensation expense was $8.7 million, compared to $1.6 million last year.Q1 adjusted earnings from operations were $65.4 million or 12.8% compared to $29.7 million or 9.1% last year. The increase in margin reflected efficiency gains made in our cost structure, improved program execution and higher after-sale service revenues compared to a year ago. Excluding acquisitions, our core business operated at a 14.1% adjusted earnings from operations margin. Operating margins from our acquired businesses were 8.2%. As a reminder, CFT operated at a low single-digit EBIT margin prior to acquisition. We expect to realize cost and revenue synergies over the next 3 years that will add earnings of approximately EUR14 million, consistent with our previously announced integration plan. After operating the business for a full quarter, we are confident that we can unlock value in our stated time frame.With respect to BioDot, as I noted, part of the business is benefiting from COVID-related activity. As these COVID tailwinds reduce over time, improvements to BioDot's business will be pursued through cost and revenue synergies we have identified and targeted growth in entire margin consumables and aftermarket service business. While we're in the early stages, integration activities are progressing well.Moving to the balance sheet. In Q1, we generated cash from operations of $48.4 million, compared to cash generation of $47 million last year, as higher income was partially offset by an increase in working capital investment. Our noncash working capital as a percentage of revenue was very low at 5.4% in Q1, down from 6% in Q4 and well within our target of maintaining working capital as a percentage of revenues below 15%. While we're pleased with this result, we do expect our noncash working capital investment to increase during fiscal '22.We invested $14.3 million in CapEx and intangible assets in Q1 compared to $5.7 million last year. Higher investments primarily related to the expansion and improvement of certain manufacturing facilities and investments in IT. As a reminder, our CapEx budget for fiscal '22 is $50 million to $60 million, an increase over last year, reflecting our plans to add capacity to support growth and continue to invest in innovation. We ended the quarter with good liquidity, consisting of cash of $216 million and availability on our credit facilities of approximately $664 million. From a leverage standpoint, our June net debt to adjusted EBITDA ratio was 1.7:1. We have further room to deploy capital to pursue our strategies within our normal course target leverage range of up to 2.0x to 2.5x.In summary, Q1 was a strong start to the year, including adjusted EPS of $0.48, up 182% over a pandemic impacted quarter last year. The investments and improvements made in our business are driving growth, resiliency and margin expansion. Our teams executed efficiently to meet customer needs while maintaining a safe working environment. Through our M&A activities, we've created a broader platform in food and beverage by adding CFT as a complement to MARCO, while the additions of BioDot and CIN provide us with new capabilities in Life Sciences. Going forward, with a record order backlog, a strong balance sheet and available liquidity that combined to provide ATS with a solid foundation to pursue our growth strategies.Now, we will open the call to questions from our analysts. Operator, could you please provide instructions? Thank you.
[Operator Instructions] And your first question comes from Mark Neville from Scotiabank.
Great results. Maybe just start with, I just want to understand the margin, I guess, sort of apples-to-apples, it looks like EBIT margin is up roughly 170 basis points sequentially. I appreciate some of the things you mentioned, but just maybe try to help us understand what drove the quarter-over-quarter performance and maybe try to piece it apart, if you could?
Yes. Mark, so if I compare -- so you're asking for a comparison to Q4, is that correct?
Yes. Again, the -- I think your 14.1% this quarter, ex acquisition last quarter, you were at 12.4%.
Okay, so core business. Yes, I mean, we're seeing a couple of items. So first, we're realizing benefits from our improved cost structure. So we undertook restructuring activity last year, and we're seeing the payback on that. We've also continued to have really good program execution in our core business. And we've had good progress on our other margin expansion initiatives. So it's -- as I think about it, it's all normal course, good execution in the business.
Maybe just a question. It doesn't feel like there's any impact, but maybe, Andrew, I'm just curious as we're hearing at least every manufacturing company we cover talk about inflationary pressure, supply chain issues. I'm just curious if you're actually seeing any impact? It doesn't seem like it, but I'm curious if there's any impact?
Look, the short answer is we really haven't seen anything material to date. But as I said, our supply chain teams are remaining and they're focused on being vigilant on this aspect. And a couple of comments to wrap that summary. Where we are seeing an impact is when we've seen, call it, shorter lead time products or quick turn products, call it a day or several days, those have moved out to 3 to 4 weeks and at times longer. And so the shorter term items have created a bit more of a challenge. Unfortunately, we've been able to have workarounds, where we know the lead times, and we can work to mitigate those areas that we've seen an impact on.Additionally, so when you think about the inflationary areas, and we're not immune to those areas. We also have a very strong playbook in this area of our business to go after where we want to keep driving the supply chain and longer term strategy in place around where we're going to continue to move our supply chain. So where we see pressure and where we've seen, call it, this area rise, we've been able to be proactive and mitigate or even continue our trajectory and our margin expansion. So overall, I'd say the team has just done a terrific job, and we're really pleased with the progress. That said, it is something we're being very, very focused on and very vigilant around to ensure that we continue to mitigate impact across ATS.
All right. I got a bunch of other questions, but I'll get back in queue. Thanks.
Your next question comes from Cherilyn Radbourne from TD Securities.
So Andrew, I think the supply chain disruption resulting from COVID has been really unprecedented in terms of the duration and severity. So first question is, could we get a bit of an update on your customer interactions and just what they're thinking in terms of reshoring and other adjustments to their supply chain?
Sure. And Cheryl, I am going to piece this one a part a little bit, and I'm going to talk about, first and foremost, the order process, and we haven't seen customers pulling in or pushing out based on this. And a natural area you would go to is automotive, and that would be a natural consideration. But in our automotive, our focus has been on the EV and battery pack and tests and module part of the process, which is core to that shift. And so we haven't seen an impact here from a push out or pull in, and it's been aligned with customers' long-term plans for their capital spending and capital deployment.If we step back then and look at the onshore, we call it onshore and supply chain derisking. We don't separate those two, we kind of bucketize them both. When I've talked to customers, and as you're well aware, I talked to customers on a frequent basis, I'd say, roughly 50% are talking through this and about 25% of placed orders with our business. Additionally, when you look at some of the awards we've gotten, well, they might not be aligned to this, they're really wrapped around expansion of capacity. And so if you look at that $120 million order that we won on the medical device business in Q1, which is a big win, a big order for us and certainly has been an area that we've been aligned with this customer for some time. Their focus was around being able to build out their capacity to meet demand. And they saw demand increase from this environment, the situation, and they align to say, our strategic direction is we need to build that capacity than demand out. So we have seen some shift there, I would say, is it directly in line with onshoring? No, it's more in line with their strategic plan around building our capacity and capability, and automation is a natural, call it, consideration for those expansions.So overall, we do think this is an area that's going to continue to support automation, we view it's an area that certainly is going to be a key focus for us, but we haven't seen, call it, an increase in demand as of yet.
Okay. My second question is probably more for Ryan. The year-over-year increase in parts sales was pretty massive. Just wondering if you could speak to how much of that was organic versus acquired and qualitatively give some color on what that means from a mix perspective?
Yes, Cherilyn. So part of that certainly was due to acquisition, the majority was due to acquisitions. So CFT has kind of a large parts business. There was some -- there was year-over-year organic growth in the core business as well.
And just directionally, is that positive from a mix perspective?
In terms of margin, are you asking?
Yes.
Yes. So generally speaking, yes, generally speaking, yes.
Your next question comes from Justin Keywood from Stifel GMP.
Nice to see the results. For the CFT acquisition, there's implied some good organic growth in the quarter and setting up pretty well as far as the outlook for the vertical. I'm just wondering if you can provide some context on what the demand drivers for the food and beverage space and if the inflationary backdrop is impacting any of the demand?
Yes, Justin. So we have seen a nice progress here. I'll just start with, it's still early with CFT as part of our journey. And as I highlighted in my opening remarks, we're pleased with the playbook that we've launched for the integration, the engagement from the team. So as I step back and look at this business, they did 4 Kaizen events through the quarter and it just highlights the drive for this organization to really, call it, continue to improve and focus on their markets, where we've also seen is we've seen a nice balance around potential and the strong customer engagement from a CFT.One of the area I would just highlight is, we identified some synergies early on in the process and while it's early, and I state that directly, we've only had them for several months of our business, we have already started quoting the CFT robotics in some of our Life Sciences business. I'm so pleased with the technology and pleased with the progress, and certainly, it's the synergy aspect we're seeing some real strong potential to realign around what we signed up for delivering the results.Ryan, is there anything you would add to that?
Yes, so Justin, just a couple of items. So as I talked about in my remarks, there's some seasonality to shift this business, and so when I look at the margin performance this quarter, they're a little bit of ahead of -- they're executing well and some of that is really did put some cost synergies we identified, and some of that is higher volumes and part of that's really the seasonality.
And then for acquisitions, is the pipeline still active, or is the focus on integrating the recent acquisitions that were just completed? And if you can just provide us an update on the targeted verticals that you could possibly enter if it's new or existing? And also what you see as the capacity for additional M&A?
Sure. And headline here, Justin, it is and remains active. The funnel is healthy, and it's focused both on platforms as well as tuck-ins. And for instance, in the quarter, we announced CIM and BioDot, both very attractive additions to ATS, and we view we can help those businesses achieve full potential. And so the funnel remains healthy. It's no surprise on the markets that we've been targeting. And we view that our ability to cultivate is only increase. And casing points after we acquired CFT, one of the benefits we had was certain customers or certain, call it, competitors or in the same area of processing reached out and really aligned around whether it's a potential discussion on calculation or around the potential partnership, and it's just an area that we certainly have continued to drive. And as I will always state, we are disciplined and when we identify the right targets, we can move at a very fast pace.
And just to answer your question on capacity, so from just purely balance sheet, we still have ample capacity in the $500 million, $600 million range and it really depends on price and the financial profile of the asset, but that's the general range that we would have available today.
[Operator Instructions] Okay. Mr. Hider, there are no further questions at this time.
Thanks, operator. Before we let you go, a reminder that we will host our Virtual Annual Meeting tomorrow, beginning at 10:00 a.m., details are available in the management information circular and on our website. This is another strong quarter for the company and a great way to start our fiscal 2022. I'd like to recognize the hard work and dedication of our teams across ATS that made this possible. Thank you for joining us today. I look forward to speaking to you on our Q2 call in November. Stay safe, and goodbye for now.
Ladies and gentlemen, this concludes your conference call for today. We thank you for participating and ask that you please disconnect your lines.